Monroe Dunaway Anderson

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

Retrieved on: 
Monday, March 25, 2024
IIT, Radiation, IO, Carcinoma, Survival, NSCLC, Entrepreneurship, Monroe Dunaway Anderson, Patient, Journal, Merck, Overalls, MD, Lung, Neoplasm, Safety, EP, SITC, PFS, PD-L1, Platinum, Horn, Immunotherapy, PD-1, Medical imaging

This Phase 2 trial will evaluate the efficacy and safety of Pembrolizumab, Plinabulin plus EP in 1L ES-SCLC.

Key Points: 
  • This Phase 2 trial will evaluate the efficacy and safety of Pembrolizumab, Plinabulin plus EP in 1L ES-SCLC.
  • KEYNOTE-604 study revealed that 12-month PFS rate in patients with pembrolizumab plus EP is 13.6% vs. 3.1% with placebo plus EP.
  • Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell Lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
  • An Open-Label, Single-Arm, Phase II Study of Pembrolizumab, Plinabulin Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer.

Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors

Retrieved on: 
Thursday, March 21, 2024
Cancer, Principal, Enzyme, DNA repair, Biochemistry, Survival, Professor, Monroe Dunaway Anderson, Patient, Neoplasm, DNA, History, Breast, Prostate, Protein, University, MD Anderson Cancer Center, PARP, Therapy, ALC1, Chromatin, CSO, LP, Pharmaceutical industry

EIS-12656 is a small molecule designed to treat tumors that are refractory or resistant to PARP inhibitors.

Key Points: 
  • EIS-12656 is a small molecule designed to treat tumors that are refractory or resistant to PARP inhibitors.
  • By hindering DNA repair, PARP inhibitors cause tumor cell death, and they have been effective therapies for many ovarian, breast, prostate, and pancreatic cancers.
  • EIS-12656 inhibits the chromatin remodeling enzyme ALC1, which is critical to the DNA repair process associated with PARP activation.
  • EIS-12656 was developed by Eisbach to disrupt DNA-damage-dependent PARP activation at an early stage of the repair process.

Koning Health Celebrates Milestone of 150,000 Scans Worldwide

Retrieved on: 
Wednesday, March 27, 2024
MRI, Radiology, Monroe Dunaway Anderson, Breast MRI, Health, Patient, Woman, BCT, Google Images, DBT, Physician, Medical imaging

NORCROSS, Ga., March 27, 2024 /PRNewswire/ -- Koning Health , leader in advanced medical imaging technology, is proud to announce a significant milestone in its journey to revolutionize diagnostic imaging.

Key Points: 
  • NORCROSS, Ga., March 27, 2024 /PRNewswire/ -- Koning Health , leader in advanced medical imaging technology, is proud to announce a significant milestone in its journey to revolutionize diagnostic imaging.
  • Since its inception, Koning has been at the forefront of medical imaging technology, continually pushing the boundaries of what is possible.
  • The completion of 150,000 scans is not just a number; it represents countless lives impacted, diagnoses clarified, and treatments optimized.
  • Experts are taking note of the capabilities presented with Koning Vera Breast CT, including physicians like Dr. David Bodne.

Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML

Retrieved on: 
Wednesday, March 27, 2024
AML, Monroe Dunaway Anderson, CRC, Patient, Acute myeloid leukemia, Virus, University, United States patent law, Clinical trial, FDA, STS, Pharmaceutical industry

HOUSTON, March 27, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received an Issue Notification from the United States Patent and Trademark Office (USPTO) for U.S. Patent number 11,951,118 titled, "Preparation of Preliposomal Annamycin Lyophilizate" (the '118 patent') to be issued on April 9, 2024 to Moleculin and The University of Texas System Board of Regents.

Key Points: 
  • Moleculin's novel candidate for the treatment of acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases (STS lung mets) uses a unique lipid-based delivery technology.
  • In addition to the expected '118 patent, Moleculin has additional patent applications pending in the U.S. and in major jurisdictions worldwide.
  • Issuance of this patent underscores the importance and proprietary nature of the innovation that makes this next generation anthracycline possible."
  • Annamycin is Moleculin's next-generation anthracycline, initially expected to fulfill a significant unmet need for the 2nd line treatment of relapsed or refractory AML patients.

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

Retrieved on: 
Tuesday, March 12, 2024
CONNECT, Internal medicine, University, Growth, Biotechnology, Novo Nordisk, Hematology, Science, AML, Monroe Dunaway Anderson, Executive, Patient, SAN, Novartis, FLT3, Head, Drug, Therapy, Drug development, Sangamo Therapeutics, Molecular Partners, MorphoSys, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D.
  • as Executive Vice President and Chief Medical Officer.
  • Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology.
  • Prior to joining Rigel, Dr. Rojkjaer held several leadership positions in clinical development and medical affairs at biotechnology and global pharmaceutical companies, having most recently served as Chief Medical Officer of Sangamo Therapeutics.

Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma

Retrieved on: 
Monday, March 11, 2024
Doctor of Philosophy, MD, Monroe Dunaway Anderson, Entrepreneurship, Safety, University, Genome, Patient, Writing, TCR, Haematopoietic system, Biology, Trial of the century, DNA, NY-ESO-1, Pharmaceutical industry

Syena has an exclusive licensing agreement for MD Anderson’s TCR-NK technology platform.

Key Points: 
  • Syena has an exclusive licensing agreement for MD Anderson’s TCR-NK technology platform.
  • This first-in-class engineered cell therapy comprises cord blood-derived natural killer cells that express an affinity-enhanced TCR targeted against the NY-ESO-1 antigen.
  • The Phase 1/2 clinical study will assess the safety and efficacy of NY-ESO-1 TCR/IL-15 NK in patients with relapsed or refractory multiple myeloma.
  • NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma, making this a suitable indication for demonstrating proof of concept for Syena’s TCR-NK technology platform.

TOMI Expands SteraMist iHP Corporate Service Contracts and Clients

Retrieved on: 
Thursday, March 7, 2024
Hydrogen, DARPA, Acquisition, Pfizer, Hospital, Rocky, Restaurant, Hydrogen peroxide, Food safety, Disinfectant, Annual report, Health, Growth, Cell, Monroe Dunaway Anderson, Horsepower, Meat, University, School, Supervisor, Decontamination, MD Anderson Cancer Center, Police, Medication, Trust, Paint, Corporation, Partnership

FREDERICK, Md., March 07, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced an expansion in its SteraMist iHP Corporate Service contracts, reaffirming its position as a leading provider of decontamination services to corporate clients in the life sciences industry.

Key Points: 
  • FREDERICK, Md., March 07, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced an expansion in its SteraMist iHP Corporate Service contracts, reaffirming its position as a leading provider of decontamination services to corporate clients in the life sciences industry.
  • SteraMist iHP technology is becoming the standard decontamination technology in the life sciences sector and academic institutions with a broad spectrum of clients equipped with mobile systems, custom integrations, and service contracts.
  • In a notable development, Rising Pharmaceuticals has entered into an ongoing annual contract with TOMI’s SteraMist iHP Corporate Service following the acquisition of a building previously serviced by the team.
  • SteraMist iHP Corporate Service managed to decontaminate our entire facility quickly without causing harm to the infrastructure or our sensitive equipment.

Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets

Retrieved on: 
Tuesday, March 5, 2024
Trichloroethylene, Therapy, CG1, Doctor of Philosophy, TCE, MD, Immunotherapy, Monroe Dunaway Anderson, AACR, Cathepsin G, Annual general meeting, Safety, MD Anderson Cancer Center, University, Mass spectrometry, Myeloid leukemia, TCR, Malignancy, CTSG, Cancer, Pharmaceutical industry

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Crossbow Therapeutics, Inc., a biotechnology company focused on advancing T-Bolt™ therapies, a novel class of antibody therapeutics that mimic T-cell receptors (TCR-mimetics), today announced the nomination of its first development candidate, CBX-250, a first-in-class, potent, and specific T-cell engager (TCE) for the treatment of myeloid leukemia.

Key Points: 
  • The oral presentation will provide an overview of the preclinical characteristics of CBX-250, which targets a cathepsin G (CTSG) peptide-human leukocyte antigen (pHLA) complex.
  • The complex is abundantly expressed on leukemic cells, but not on normal cells, allowing CBX-250 to target cancer cells efficiently while sparing normal myeloid cells.
  • “Nominating CBX-250 as a development candidate validates our initial scientific hypothesis, and it brings us a step closer to entering the clinic and ultimately helping to cure cancer,” said Briggs Morrison, Chief Executive Officer of Crossbow.
  • Working with MD Anderson’s ORBIT platform, a core component of the institution’s Therapeutics Discovery division , Dr. Molldrem led the development of a TCR-mimetic binder to the CG1 pHLA complex, which Crossbow licensed for the development of off-the-shelf cancer immunotherapies.

Verismo Therapeutics Announces Opening of Second Clinical Site for STAR-101 Phase 1 Trial

Retrieved on: 
Thursday, March 7, 2024
Mesothelioma, MD Anderson Cancer Center, Patient, Ovarian cancer, Therapy, Monroe Dunaway Anderson, Verismo, Entrepreneurship, University, Pharmaceutical industry

PHILADELPHIA, March 7, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR-T company developing the novel KIR-CAR platform technology, today announced that it has activated a second clinical site for its STAR-101 Phase 1 clinical trial at The University of Texas MD Anderson Cancer Center.

Key Points: 
  • STAR-101 is a multi-center clinical trial designed to evaluate Verismo Therapeutic's lead candidate, SynKIR™-110, for the treatment of mesothelin-overexpressing ovarian cancer, malignant pleural mesothelioma, and cholangiocarcinoma.
  • "This milestone marks the steady progress towards our goal of bringing SynKIR™-110 to as many patients as possible," said Dr. Bryan Kim, Co-Founder and CEO of Verismo Therapeutics.
  • Verismo has previously announced that SynKIR™-110 received Orphan Drug Designation and Fast Track Designation for the treatment of mesothelin-expressing mesotheliomas.
  • For more information about the STAR-101 clinical trial, please visit ClinicalTrials.gov NCT05568680 .

Historic Opportunity to End Breast Cancer Launched Today

Retrieved on: 
Tuesday, January 30, 2024
Hope, Woman, Patient, Monroe Dunaway Anderson, Research, NBC News, Roswell Park, Cancer, Science, Friends, Survivor, Breast cancer, University, Vaccination, Immunotherapy, Recurrence, News, Dana–Farber Cancer Institute, Cleveland Clinic, Government, Vaccine, Immune system

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Today two high-profile breast cancer survivors, with the nation's top breast cancer doctors backing them, launched the Pink Eraser Project that will accelerate development of life saving breast cancer vaccines, aiming to shorten the process by 25 years.

Key Points: 
  • NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Today two high-profile breast cancer survivors, with the nation's top breast cancer doctors backing them, launched the Pink Eraser Project that will accelerate development of life saving breast cancer vaccines, aiming to shorten the process by 25 years.
  • "The science to end breast cancer exists by harnessing the power of our own immune systems.
  • Dahlgren and Young, both breast cancer survivors, met when Dahlgren interviewed Young about her breast cancer journey and her quest to save women from the devastating disease effects.
  • "We are at a unique moment in time when the right collaboration and funding could mean breast cancer vaccines within a decade.